Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 6206875 | Synthesis of electrophoretically restricted IgG by cultured rheumatoid synovium. | 1984 Sep | IgG synthesized by excised rheumatoid (RA) synovia was separated according to isoelectric point using chromatofocusing and isoelectric focusing. Over 30% of the IgG synthesized by 9 of 11 synovia had an isoelectric point greater than 8 (cathodal shift), while 55% of the synovia secreted IgG showing oligoclonal banding by isoelectric focusing. Oligoclonal serum IgG was seen in 17% of RA patients and in only 3% of hospitalized patients without RA. These results emphasize the selective character of the antigenic stimulus of the RA synovial lymphoid infiltrate. | |
| 133652 | Pseudo-radiculopathy in subacute trochanteric bursitis of the subgluteus maximus bursa. | 1976 Aug | Seventy patients, averaging 82 years of age, were referred for low back pain and/or a suspected herniated disk. Objective neurological deficits consistent with L5 or S1 root involvement were identified in 5 of the 70 patients. Trochanteric bursitis (TB), often mimicking radiculitis, was diagnosed in 31 patients. Trochanteric bursitis was associated with lumbosacral strain and lumbar osteoarthrosis in 21 of 31 patients and with an S1 disk in 1 of those 31 patients. Degenerative joint disease of the ipsilateral hip was present in 4 of 20 of these patients with TB. Six patients with low back pain had both hip and knee arthritis (including two patients with rheumatoid arthritis). Three patients had degenerative hip disease without low back complaints. The remaining patient had TB associated with left hemiparesis. All patients had limitation of lumbosacral motion. Patients with arthritic hips had apparent shortening of the affected leg of one-half inch or greater. Trochanteric bursitis is a common complication of lumbosacral strain, frequently mimicking radiculopathy. Gait alteration associated with back pain or static traction on gluteal musculature during rest therapy may be predisposing factors. The association of TB with hip disease and/or leg length discrepancies was again confirmed. | |
| 3895360 | [Ulcerogenic potential of corticoids in man: a reality or methodologic artifact?]. | 1985 | It is generally accepted that glucocorticoids are ulcerogenic. The different pharmacological, biological and clinical arguments on which this opinion is founded are reviewed. It is concluded that, particularly in pneumology, none of them is sufficiently sound to justify the prophylactic measures generally systematically used. In fact it appears that glucocorticoids are not primary offenders by rather potentiate ulcerogenesis. Prophylactic measures are therefore indicated only in ulcerogenic conditions such as association with non steroidal anti-inflammatory agents or in some pathological situations such as rheumatoid arthritis and severe cirrhosis. These conditions are generally not encountered in pneumology and therefore the ulcerogenic risk in this case can be considered as non existent. | |
| 6678689 | Hypothalamic-pituitary-adrenal (HPA) axis function in patients receiving long-term intra-a | 1983 Jun | The hypothalamic-pituitary-adrenal (HPA) axis function of eight patients with rheumatoid arthritis receiving regular intra-articular methyl prednisolone acetate was studied. Tests of the HPA axis 5-7 weeks after the last injection revealed suppression in two patients. Some patients receiving intra-articular corticosteroids may therefore have abnormal responses to stress. | |
| 6823487 | A serious complication following medical-grade silicone injection of the face. | 1983 Feb | A serious complication following MDX4-4011 Dow-Corning silicone for injection to the face is reported. The patient developed inflammatory lesions 11 years after her last silicone injection for what was felt to be Weber-Christian disease. The patient also had a diagnosis of rheumatoid arthritis and a questionable history of mycoplasm infection. She eventually required excision of the right facial area with flap reconstruction. There is at least one other investigator who has had inflammatory complications following silicone injection to a patient with Weber-Christian disease. For these reasons, caution in using liquid silicone in patients who might have Weber-Christian disease is recommended. | |
| 152806 | Ultrastructure of the skin of patients treated with sodium aurothiomalate. | 1978 Feb | Skin biopsies from cases of rheumatoid arthritis treated with sodium aurothiomalate were examined with the electron microscope. Intralysosomal gold deposits were found in the macrophages of both normal-looking skin and from areas of erythematous rash that had developed as a toxic manifestation of gold therapy. The main difference between affected and normal-looking skin was the presence of numerous mast cells in the former. It is hence suggested that the dermatologic side-effects of gold are probably mediated by the release of vasoactive substances from mast cells and that vigorous administration of antihistamines to neutralise the liberated products of mast cells or an agent that interferes with degranulation of mast cells might have a palliative effect on the skin rash that sometimes develops during chrysotherapy. | |
| 6361702 | Evaluation of new indomethacin dosage forms. | 1983 Nov | Indomethacin, an indole derivative nonsteroidal anti-inflammatory drug, has been available since the early 1960s in gelatin capsules. In 1982, a sustained release product, Indocin SR, was marketed. Awaiting marketing approval is a unique controlled release form of indomethacin, Indos. The disposition of indomethacin includes enterohepatic cycling and extensive metabolism to inactive metabolites. Enterohepatic cycling makes interpretation of bioavailability estimates of indomethacin dosage forms difficult. The relationship of indomethacin plasma concentration to therapeutic effects and side effects is inconclusive. It appears in vivo prostaglandin inhibition occurs at very low plasma concentrations that are achievable with all available dosage forms. Indocin SR is a sustained release capsule of indomethacin designed to deliver 25 mg of drug immediately and 50 mg gradually. Absolute bioavailability of the product is 80%. The plasma concentration-time curves do not show good sustained release characteristics; after four hours plasma concentrations resemble those seen with a single dose of regular capsule. The cost compared with Indocin is competitive. Indos is a zero-order release form of indomethacin. It is a unique drug delivery system that shows good controlled release characteristics. Bioavailability is 85%. Both Indocin SR and Indos are apparently therapeutically equivalent to indomethacin capsules. In elderly patients, Indos has been shown to be associated with fewer side effects than Indocin. Both Indocin SR and Indos have the advantage of once or twice daily dosing. | |
| 1103765 | Clinical experience with naproxen in rheumatoid arthritis. | 1975 Nov | A total of 42 patients participated in three controlled clinical trials, each of different design, to demonstrate the efficacy and safety of naproxen in the treatment of rheumatodi arthritis. First, a double-blind comparison of aspirin and naproxen was made in 24 patients. As judged by objective and subjective measurements of disease activity, naproxen was at least as effective as aspirin and the incidence of severity of side effects were less with naproxen than with aspirin. Second, the safety and efficacy of naproxen administration was followed in 42 patients for up to two years. Third, the continued efficacy of naproxen during these two years was tested by interspersing a short period of double-blind placebo administration for some patients. The observations made in this clinical study suggest that naproxen is an effective and well-tolerated drug in the long-term treatment of rheumatoid arthritis. | |
| 6374502 | [Therapeutic action of Piroxicam administered rectally in rheumatic diseases. Controlled d | 1984 Apr 7 | In a 15 day double-blind clinical trial 39 patients affected with rheumatic disease have been enrolled to evaluate the therapeutic effect of rectal administration of Piroxicam, in comparison with Indomethacin. At the end of the study, 20 patients had been treated with Piroxicam and 19 with Indomethacin. Nine patients in the Indomethacin group and one in the Piroxicam group dropped-out. Both drugs safety resulted good in the patients who completed the study, whereas 5 out of 10 dropped-out patients stopped the trial in consequence of severe side-effects of Indomethacin. Piroxicam induced a very good improvement in 76% of the patients, moderate in 19% and no improvement in 5%; Indomethacin induced a very good improvement in 75% of the patients, moderate in 15% and no improvement in 10%. No significative modifications resulted from the control of the laboratory blood tests. Piroxicam (30 mg/die) showed a therapeutic activity similar to Indomethacin (100 mg/die). The rectal administration of Piroxicam can be then considered a very good alternative to the oral one, particularly in the patients in which oral use of NSAID is counter-indicated. | |
| 6465162 | Pharmacokinetics of ibuprofen. | 1984 Jul 13 | The pharmacokinetics of ibuprofen (Motrin) are best described by a two-compartment open model. Ibuprofen pharmacokinetics are only minimally influenced by advanced age, the presence of alcoholic liver disease, or rheumatoid arthritis. Levels of ibuprofen in breast milk are negligible. In addition, ibuprofen can be combined with acetaminophen without altering the pharmacokinetic profile. However, although not yet clinically proved, the concomitant use of ibuprofen and aspirin appears to reduce ibuprofen plasma levels to less than half those observed with ibuprofen alone. | |
| 6442052 | [Experiences to date with oral gold therapy]. | 1984 | Auranofin is the first oral gold therapy known to be effective at relatively low toxicities. Extensive clinical trials in rheumatoid arthritis have recently been complemented by first experiences in juvenile chronic polyarthritis. For the time being, the drug should, therefore, be confined to these conditions. It is not indicated in ankylosing spondylitis and in other seronegative arthropathies. Indications mainly include failure of antimalarials, early erosive arthropathies and contraindication of injection therapy. The drug may also be used as an alternative to intramuscular gold, but should not be administered to responders to other chronic antirheumatics and in late or end-stage disease. | |
| 7014873 | Myasthenia gravis and D-penicillamine. | 1981 Jan | There has been some uncertainty as to whether the apparent association between myasthenia gravis (MG) and D-penicillamine (D-P)-treated rheumatoid arthritis (RA) could be due to chance or whether the drug is responsible. In the absence of D-P, RA is found in association with MG, but this may simply reflect the high prevalence of RA. Although MG may be more common than expected after D-P treatment of RA, it probably occurs in only approximately 1% of such patients. In these circumstances, it is difficult to prove that D-P can induce MG, but compelling evidence in support for this possibility comes from the finding of differences between autoantibodies when spontaneous and D-P-associated MG are compared. These serologic differences could be explained in terms of an effect of D-P on antigen presentation and/or immunoregulation. | |
| 183273 | [Infections and immunosuppressive agents in rheumatology]. | 1976 Jun 9 | The authors review the problem of infection occurring in patients with chronic inflammatory rheumatism, e.g. rheumatoid arthritis, and lupus erythematosus, treated with cytolytic drugs for immunodepressive reasons. From their investigation, it seems that there is a high frequency of bacterial and mycotic and viral infections in these patients, but controlled investigations seem to show quite definitely that the frequency of these infections depends on the disease itself. The risk does not seem to be increased by cytolytic drugs. The only exception is herpes which appears in 10 to 20% of patients treated with immunosuppressive agents, as against 2% in a controll series. The other virus diseases did not have an abnormally high frequency. The conclusions are, of course, only of value for the types of treatment used in rheumatology. | |
| 796945 | Results of the rectal administration of ketoprofen in fifty-two patients. | 1976 | The results of a clinical study of ketoprofen suppositories suggest that the drug is effective when given in this way. It is suggested that, in the treatment of inflammatory rheumatic disorders, advantage should be taken of the longer duration of action of ketoprofen suppositories to prescribe their administration early in the morning and before retiring. Local intolerance occurred in only 4 of 52 patients. | |
| 6410868 | Assessment of craniocervical junction and atlantoaxial relation using metrizamide-enhanced | 1983 May | Metrizamide-enhanced computed tomographic (CT) myelography has made it easier to define the relation of the spinal cord to the vertebral canal. A flexion-extension metrizamide-enhanced CT technique has been developed to study the craniocervical junction that refines evaluation of the relation between the spinal cord and the foramen magnum, atlas, and axis. This technique was used to study 15 adults who had had a structurally normal examination of the upper cervical cord and foramen magnum. The average movement of the upper cervical cord was shown to be 1 mm. The advantages of the flexion-extension metrizamide-enhanced CT examination were evident in 10 other patients who had a variety of craniocervical junction pathologies. | |
| 7310203 | [Development of clear zone after total hip replacement (author's transl)]. | 1981 Jun | For studying the durability of Charnley-Müller's total hip prosthesis, 141 joints of the cases which had past at least 5 years from the operation were followed up by means of X-ray pictures to reveal the processes of CZ (clear zone at the interface between bone and cement) progress and loosening generation. Results 1) CZ which occurred once never disappeared and progressed in many cases. 2) The progress of CZ was supposed to be related to age and disease, but no relation was recognized with biomechanical factors. 3) The incidence of CZ was 83.7% on the acetabular side and 49.6% on the femoral side. 4) CZ of Stage I and II occurred within 1 year after the operation in many cases and CZ of Stage III and IV tended to increase about 3 years and 4 years after the operation, respectively, in the acetabular side, while in the femoral side Stage I occurred within 1 year in many cases, Stage II and III increased about 3 years after and Stage IV did about 4 years after. 5) The term for progressing from a stage to the next one considerably varied till Stage III, including non-progressive cases, but the term from Stage III to Stage IV was within 3 years in all the cases. 6) The durability of Charnley-Müller's total hip prosthesis observed in X-ray pictures was as low as 63.1%, 89 out of 141 joints 5 years after the operation, and it would be lower for a long time. The durability was particularly low in young cases of osteoarthritis. 7) The X-ray findings of loosening preceded clinical findings; thus precise interpretation of X-ray findings is useful for decision of prognosis and therapy. | |
| 6091273 | Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): gas-liqu | 1984 Aug | Using GLC, multiple adrenal corticosteroid urinary metabolites, including androgenic-anabolic, glucocorticoid, pregnanediol, and pregnanetriol, were measured in eight ambulatory female RA patients and eight matched normal control subjects on baseline, ACTH-, and metyrapone-stimulation days under carefully monitored clinical research center protocol. Neither group had been treated previously with any steroid hormones. The 11-deoxy-17-KS metabolites, derived from adrenal androgenic-anabolic steroids, and comprising androsterone, etiocholanolone, and DHA, were significantly lower in RA patients on baseline (P less than .001), ACTH (P less than .005)-, and metyrapone (P less than .02)-stimulation days. To the contrary, the 11-oxy-17-KS metabolites, derived mainly from glucocorticoids, showed some lowered excretion at baseline (P less than .05), but none on ACTH- or metyrapone-stimulation. RA patients had lower tetrahydrocortisone (P less than .001) and tetrahydro-11-deoxycortisol (P less than .01) excretion at baseline, but not during ACTH- or metyrapone-stimulation, than control subjects. Pregnanetriol excretion was lower (P less than .005) in RA patients than control subjects only during ACTH-stimulation. No difference was found between groups in tetrahydrocortisol or pregnanediol excretion on any day studied. Under conditions of oral metyrapone administration (750 mg every four hours for seven doses) each control subject increased their DHA excretion, but no RA patient showed an increase over baseline excretion (P less than .02). Except for 11-deoxy-17-KS, no difference was found in the other metabolites studied during metyrapone stimulation, ie, pregnanediol, pregnanetriol, tetrahydro-11-deoxycortisol, and tetrahydrocortisol. The 24-hour oral metyrapone test provided a greater stimulus to total 11-deoxy-17-KS excretion than an eight-hour intravenous ACTH test in control and particularly RA (P less than .01) subjects even though the DHA excretion decreased in the RA groups. Our findings of lower adrenal androgenic-anabolic metabolite excretion in female RA patients than normal matched control subjects under various conditions and other supportive androgenic hormone and metabolite studies reviewed in the English reports suggest an abnormality of adrenal androgen synthesis or metabolism in RA, whether it be a primary predisposing or secondary factor in disease. The recognized female sex preponderance and age-specific patterns of occurrence of RA are consistent with adrenal androgenic function in adrenarche, adrenopause, and later changes in aging. Metabolite excretion patterns at baseline, ACTH-, and metyrapone- stimulation indicate the greatest relative | |
| 817135 | [Acroparesthesias in plexus lesions: clinical aspects and treatment (author's transl)]. | 1975 Jun 20 | The author delimits the so-called brachial dysparesthesias from the "true acroparesthesias", the actual carpal tunnel syndrome. Dysparesthesias may be caused by cervical ribs, the scalenus syndrome and mixed forms of various abnormalities. In addition to a cervical rib, e.g. changes in the costoclavicular joint may be present, or an abnormal position of the subclavian artery. Also, lesions of nerves and vessels may emanate from the neighboring organs, as from vertebral metastases, enlarged lymph nodes etc. Generally, the treatment is conservative temporizing. Only severe cases with a confirmed diagnosis require surgical correction. | |
| 7144330 | Rat adjuvant arthritis as a model to test potential antirheumatic agents. | 1982 Aug | Adjuvant arthritis was induced in male Sprague-Dawley rats by a subcutaneous injection of Mycobacterium tuberculosis in sterile paraffine oil into the base of the tail. The effects of the immunomodulating drugs N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium (CCA), d-penicillamine and thiabendazole were compared to those of the anti-inflammatory drugs indomethacin, tolfenamic acid and prednisolone. All the anti-inflammatory drugs were highly protective. Of the immunomodulating drugs thiabendazole also showed dose-related inhibitory effect. CCA had only a negligible effect and d-penicillamine enhanced the activity of the arthritic syndrome. An aggravation of the arthritis also occurred after pretreatment with d-penicillamine for 30 days before the induction of arthritis. The complement inhibiting agents epsilon aminocaproic acid and heparin enhanced the symptoms of the adjuvant arthritis as did d-penicillamine. We suggest that the effects of the immunomodulating drugs are dependent on the dose used and the stage of the disease at the beginning of treatment. | |
| 628198 | [Myasthenic syndrome during penicillamine treatment (author's transl)]. | 1978 Feb 1 | The clinical and electrophysiological findings in 2 men who had developed a myasthenic syndrome after taking penicillamine for rheumatoid arthritis will be described. The symptoms began with dysfunction of the eye muscles following a generalised muscle weakness. Course of illness after withdrawal of penicillamine was not uniform. In one of the patients a complete remission occurred within a year. The other became steadily worse and required continuous treatment with cholinesterase inhibitors. Electrophysiological examinations showed neuromuscular blockade, posttetanic exhaustion, posttetanic potentiation was found in one patient only. An immunopharmacological block of acetylcholine receptors induced by penicillamine is discussed from a pathogenetical point of view. |